To review the recent studies on intensive glucose control and the risk of cardiovascular disease (CVD) in type 2 diabetes, to discuss potential reasons for discordant results among recent trials, and to comment on implications for clinical practice.
Introduction
Although diabetes and dysglycemia are associated with an increased risk of cardiovascular disease (CVD) [1] [2] [3] [4] [5] [6] , randomized controlled trial (RCT) evidence of the benefit of tight glycemic control (TGC) on cardiovascular outcomes has been elusive in individuals with type 2 diabetes [7, 8] . In the past year, three RCTs [9 -11 ] examining the impact of TGC on cardiovascular outcomes have been published. Together with results from the seminal longitudinal studies in diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) [12, 13, 14 ] and the Diabetes Control and Complications Trial (DCCT) [15] , findings range from reports that TGC decreases CVD risk to reports that TGC increases harm. The goal of this narrative review is to build on the quantitative findings of recent meta-analyses [16 ,17 ] to outline the differences among the studies in order to gain insight into application to different patient populations. Importantly, the benefit of TGC on preventing or delaying microvascular complications of diabetes is not in doubt [10 ,11 ,12,13,15] . The totality of the evidence suggests that TGC may be most effective in preventing cardiovascular outcomes when instituted early in the disease course, and when the cost of the therapy (in terms of weight gain and hypoglycemia), does not predominate.
Summary of recent trials
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study randomly assigned 10 251 individuals with type 2 diabetes with median HbA1c 8.1% and a history of CVD or CVD risk factors to intensive therapy (goal HbA1c of <6%) vs. conventional therapy (goal HbA1c of 7.0 to 7.9%) (see Table 1 for comparison with other trials). Patients in the intensive group were significantly more likely to require multidrug regimens to achieve this goal, and were significantly more likely to be on thiazolidinediones (91.7 vs. 58.3%), nearly all other hypoglycemic agents, and combination regimens. This trial was stopped after an interim analysis at 3.5 years of follow-up because of an increased risk of overall mortality (5.0 vs. 4.0%, P ¼ 0.04) and CVD death (2.6 vs. 1.8%, P ¼ 0.02) in the intervention group. In contrast, the study found a decrease in nonfatal myocardial infarction (MI) (3.6% in the intervention group vs. 4.6% in the conventional group P ¼ 0.004) (see Table 2 for comparison with other trials) [9 ] .
The Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study studied 11 140 individuals with type 2 diabetes and a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease. The intensive glycemic control group used sulfonylurea (glicazide)-based therapy to achieve a HbA1c goal of 6.5% or less. After a median 5 years of follow-up, the study found a benefit to TGC in the composite outcome of microvascular and macrovascular events, with the benefit largely due to a decrease in the development of macroalbuminuria (2.9 vs. 4.1%, P ¼ <0.001). The study did not find a significant difference in macrovascular events between the groups (death from CVD 4.5 vs. 5.2%, nonfatal MI 2.7 vs. 2.8%, and death from any cause 8.9 vs. 9.6%) [10 ] .
The Veterans Administration Diabetes Trial (VADT) was conducted in 1791 veterans with type 2 diabetes who had inadequate response to maximal doses of oral and/or daily insulin injections with HbA1c at least 7.5%, and targeted an absolute HbA1c reduction of 1.5% between the intervention and conventional groups.
The study excluded those with Canadian Heart Association class III or IV angina pectoris and those with New York Heart Association class III or IV heart failure [18] . Over a median of 5.6 years of follow-up, the study found no overall difference in cardiovascular or macrovascular events between the two groups (death from CVD 4.5 vs. 3.7%, death from any cause 11.4 vs. 10.6%). There was a reduction in worsening of albumin excretion rate and progression to macroalbuminuria in the intensive group [11 ] .
Although these trials were very large, duration of followup was nonetheless short relative to the duration of diabetes and expected time course of development of complications. As a counterpoint to these trials, we review the follow-up experience of the long-term diabetes RCTs.
The UKPDS study was started in 1977, with the original results published in 1998. The study enrolled a total of 4620 patients newly diagnosed with type 2 diabetes into several arms, depending on body weight: starting with sulfonylurea, insulin, or metformin for TGC vs. conventional treatment. The studies aimed for fasting plasma glucose of less than 6 mmol/l (108 mg/dl) in the intensive groups, whereas the conventional groups were treated with diet unless symptoms developed or fasting plasma glucose exceeded 15 mmol/l (270 mg/dl) [12, 13] . The sulfonylurea and insulin-based intervention group achieved a median HbA1c of 7.0%, compared with 7.9% in the conventional group, and the metformin-based group achieved HbA1c of 7.4%, compared with 8% [12, 13] . The original studies found that any intensive glucose therapy lowered the risk of microvascular complications and any diabetes-related endpoint [12, 13] . Specifically relevant to this review, the metformin group had an 11% rate of MI compared with an 18% rate in the conventional group (P ¼ 0.01) [12] .
The long-term follow-up data on this cohort provides further information about glycemic control and CVD risk. During the 10 years after the original trial, individuals in all groups maintained a median HbA1c of 8.0% or higher. Nonetheless, significant differences in macrovascular events between groups emerged. In the sulfonylurea and insulin cohorts, the event rate of MI (including fatal MI) was lower in the intensive control group (24.8 vs. 28%) for a 15% risk reduction overall (P ¼ 0.01). There was also a 13% relative risk reduction of death from any cause between the groups (42.6 vs. 47.2%, P ¼ 0.007). In the metformin group, the risk reductions were even greater: the event rate for MI (including fatal MI) was lower in the intensive group (38.8 vs. 48% P ¼ 0.005) for a 33% relative risk reduction. There was also a 27% risk reduction in death from any cause between groups (44.4 vs. 52.8%, P ¼ 0.002) [14 ] .
Although the prior trials focus on individuals with type 2 diabetes, it is instructive to compare these outcomes to those available from individuals with type 1 diabetes, who have absolute insulin deficiency. The DCCT followed 1441 young (mean age 27 years) individuals with type 1 diabetes for 6.5 years, during which the intensive treatment group achieved a mean HbA1c of 7.4% and the conventional group achieved a mean HbA1c of 9.1% [15, 19] . Subsequently, patients were followed in the Epidemiology of Diabetes Interventions and Complications (EDIC) observational study, during which mean HbA1c was approximately 8% in both groups [15] . Analysis of cardiovascular endpoints was undertaken when the prespecified event frequency was achieved in 2005. The composite cardiovascular event outcome was lower in the intervention group compared with the conventional group: the event rates were 0.38 and 0.80 per 100 patient years (P ¼ 0.007) in the intensive and conventional groups respectively. The study also found that the intensive group had a 42% reduction in risk to first CVD event (P ¼ 0.02), and a 57% reduction in risk of first nonfatal MI, stroke or death (P ¼ 0.02) [15] . 
Major differences between recent trials
It is not possible to explain with certainty why the trials reached such different conclusions, but examining differences between the trials may provide guidance and useful clinical insights (see Table 1 ).
Percentage of individuals with cardiovascular disease
The VADT (at 40%) [11 ] and ACCORD (at 35%) [9 ] trials had the highest percentage of patients with CVD at baseline. Only 12% of patients in ADVANCE had a history of previous MI (32% with MI, stroke, other) [10 ] and the UKPDS trial excluded individuals with MI within the last year, more than one vascular event, and active angina or CHF [12, 13] . DCCT excluded patients with CVD [15] .
Age and duration of diabetes
DCCT was a study of type 1 diabetes with average age of 27 and disease duration of an average of 5.5 years at the time intensive treatment was initiated [15] . Of the type 2 diabetes trials, UKPDS had the youngest patients with an average age of 53-54 years at baseline, and treatment started at the time of putative diagnosis of type 2 diabetes [12, 13] . All the other trials had an older age and longer duration of disease prior to the initiation of treatment: ACCORD, average age 62 years, duration of disease 10 years [9 ] ; ADVANCE, 66 years and 8 years [10 ] ; and VADT, 60 years and 11.5 years [11 ] .
Degree of glycemic control
The ACCORD and VADT trials had the worst average glycemic control at the start of the trials with ACCORD having an average HbA1c of 8.3% [9 ] and VADT 9.4% [11 ] . Individuals in the other trials had much better glycemic control at the start -ADVANCE 7.5% [10 ] , UKPDS sulfonylurea 7.1%, UKPDS metformin 7.3% [12, 13] . DCCT individuals, with type 1 diabetes, had an average HbA1c of 9.1% [15] .
Each study had different glycemic targets and achieved different results in different time frames. ACCORD and VADT had the greatest change in HbA1c for the intervention groups. The HbA1c in the intervention group in ACCORD started at 8.3% and reached 6.7% within 4 months and 6.4% within 1 year (compared with the conventional group which achieved HbA1c of 7.5% in 4 months and 1 year) [9 ] . The HbA1c in VADT in the intervention group started at 9.4% and reached 6.9% within 6 months (compared with the conventional therapy group reaching 8.4%) [11 ] . ADVANCE and UKPDS did not comment on how quickly the glycemic goals were reached, but the magnitude of change was less for both trials. The intervention and conventional groups in the UKPDS generally had higher levels of glycemia than the corresponding groups in the most recent trials, but still maintained HbA1c 8% or less in the conventional groups (see Table 1 ).
Hypoglycemia
Hypoglycemia was increased in all the intensive therapy groups. Considering only type 2 diabetes trials, rates of serious hypoglycemia were highest in the ACCORD and VADT trials. In ACCORD the rate of hypoglycemic events requiring medical assistance was 10.5% in the intensive treatment group compared with 3.5% in the conventional therapy group (P ¼ <0.001) [9 ] . In VADT, 24.5% of patients in the intensive treatment group had at least one serious adverse event related to hypoglycemia compared with 17.6% in the conventional therapy group (P ¼ 0.05) [11 ] . In ADVANCE 2.7% of the intensive group compared with 1.5% of the conventional therapy group had a severe hypoglycemic event (P ¼ <0.001) [10 ] . In UKPDS, the insulin treatment group had the most episodes of serious hypoglycemic events (mean proportion 2.3% per year over 10 years) followed by the sulfonylurea group (0.4-0.6% per year) [13] .
Obesity and weight gain
The UKPDS metformin arm was specifically designed to include overweight patients, thus the mean baseline BMI for that study was 31.4 kg/m 2 [12] , as opposed to the UKPDS sulfonylurea and insulin arms where the mean BMI was 27.5 [13] . The ACCORD and VADT trials also enrolled more overweight patients, with mean BMI in ACCORD at 32 kg/m 2 [9 ] and VADT at 31 kg/m 2 [11 ] . ADVANCE started with fewer overweight patients overall with an average BMI of 28 kg/m 2 [10 ] , and DCCT was 23 kg/m 2 [15] .
Individuals in the ACCORD and VADT trials had the greatest weight gain in the intervention groups. The ACCORD intensive group gained 3.5 kg, compared with 0.4 kg in the conventional group [9 ] . The VADT intensive group gained 8.2 kg compared with 4.1 kg in the conventional group [11 ] . The UKPDS trial also had significant weight gain in the insulin and sulfonylurea arms (insulin 4.0 kg, glibenclamide 1.7 kg, and chlorpropamide 2.6 kg) [13] . There was less difference in weight gain between groups in the ADVANCE and the UKPDS metformin study (ADVANCE À0.1 kg vs. À1 kg [10 ] ; UKPDS metformin: À1 kg/no change [12, 16 ] ).
Other cardiovascular risk factors
Other cardiovascular risk factors tended to improve over the course of the studies and were better controlled at baseline in the more recent studies. Space constraints prevent detailed elaboration. In general, smoking decreased in all the studies over time. Lipid profiles and blood pressure improved over the course of all of the studies except for the DCCT without significant differences between intervention and conventional therapy groups.
Power and duration of follow-up
Because ACCORD was stopped early for safety issues, it had the shortest length of follow-up with 3.5 years, though it was originally planned for 5.6 years [9 ] . Stopping a trial early biases the results toward the stopping criteria because the full length of time for events to accrue is not maintained [20] . Also in ACCORD, the mortality in both the intervention and conventional therapy groups was lower than anticipated [9 ] . Similarly, the annual rate of macrovascular events in ADVANCE was lower than expected (2.2% vs. the expected 3.0%), and the study protocol was altered after 3 years to increase its power by making the primary outcome a composite one and by extending the treatment and evaluation periods by 18 months [10 ] . VADT, too, had fewer events in both the intervention and conventional therapy groups than predicted (predicted to have a 31.6 vs. 40% event rate; observed event rates were 33.5 and 29.5%) [11 ] . UKPDS and DCCT were not powered to examine cardiovascular outcomes, but due to the long duration of follow-up in both cohorts, accrued sufficient events to yield informative data, with 21 years of follow-up of the UKPDS cohort [14 ] and 17 years in the DCCT cohort [15] .
These lower than anticipated cardiovascular event rates reflect the success of more aggressive treatment of other cardiovascular risk factors. As a result, ACCORD, ADVANCE, and VADT were underpowered to detect differences in event rates in the time period of follow-up for each study. Given the results observed, it is not clear that longer follow-up would have reversed the trends seen, though such reversals of early trends have occurred [21] . In any case, the magnitude of potential benefit compared with harm did not appear to justify continuing the ACCORD trial or further altering the protocols of the other trials.
Conclusion
Given the differences among trials and the power caveats outlined earlier, taking the results of the trials at face value seems to show that older patients with a greater burden of preexisting CVD and longer duration of diabetes do not derive cardiovascular mortality benefit from TGC, and may experience harm, particularly if TGC is associated with weight gain and hypoglycemia. As the summary of the results of the trials demonstrates, ACCORD showed cardiovascular harm. Compared with the other studies, this trial had a higher proportion of patients with preexisting CVD, older patients, initiation of intensive treatment after a longer duration of diabetes, the highest starting HbA1c with reductions below currently recommended goals, and the highest BMI with significantly more weight gain in the intensive group. ADVANCE, which achieved a similar absolute level of glycemia as the ACCORD trial, showed no cardiovascular harm and some microvascular benefit of TGC when achieved from a lower starting point and in the absence of hypoglycemia or significant weight gain; VADT had similar findings despite significant hypoglycemia and weight gain in both groups.
By contrast, the results of theUKPDS and DCCT show that maintaining TGC soon after diabetes diagnosis appears to be beneficial for cardiovascular as well as microvascular outcomes. Notably, the level of glycemia achieved in the intervention group in both of these trials approached HbA1c of 7% rather than 6%. Subgroup analyses from the three negative RCTs, which should, of course, be interpreted with caution, seem to support this. In ACCORD there was some evidence that patients who did not have a cardiovascular event prior to randomization or whose baseline HbA1c was 8.0% or less may have had fewer fatal or nonfatal cardiovascular events than patients in the conventional group [9 ] . A post-hoc analysis of the VADT trial showed that TGC initiated later in the disease course (after 15 years) was not beneficial, but TGC initiated soon after diagnosis was beneficial [22 ] . An ADA and ACC-AHA position statement found evidence to support aiming for HbA1c less than 7% for prevention of microvascular disease and recommended that same goal to prevent macrovascular disease, particularly for newly diagnosed diabetics. They recommended less stringent HbA1c goals inpatients who were at higher risk for hypoglycemia or have limited life expectancy, advanced complications, or extensive comorbid conditions [23 ] .
Although the studies summarized earlier have conflicting results, some themes emerge that are helpful in guiding therapy for patients. Overall, the rates of cardiovascular events in patients with diabetes are improving, likely due to aggressive control of other cardiovascular risk factors as has been shown to be effective in multiple clinical trials [24, 25 ] . Smoking cessation, and lipid, blood pressure and weight control should be emphasized in diabetes management. In terms of glycemic control, it is likely that TGC, aiming for HbA1c 7% or less, that is achieved without significant hypoglycemia or weight gain and is instituted early in the course of diabetes, will be beneficial. By contrast, the benefits of TGC may not extend to those with a long duration of diabetes or preexisting CVD.
